Giulia Briatico

Dr. Giulia Briatico

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
RPRiccardo Pampena
Riccardo Pampena
Vincenzo PiccoloVincenzo Piccolo
Vincenzo Piccolo
MMMarta Muscianese
Marta Muscianese
AKATHANASSIOS KYRGIDIS
ATHANASSIOS KYRGIDIS
MLMichela Lai
Michela Lai
Giuseppe ArgenzianoGiuseppe Argenziano
Giuseppe Argenziano
The current evidence on paediatric melanoma is heterogeneous, especially regarding the prognosis of different histological subtypes. We sought to systematically review the evidence on paediatric melanoma, highlighting the major sources of heterogeneity and focusing on available data on single patients. A systematic search was performed from 1948 to 25 January 2021. Only studies reporting at least one case of cutaneous melanoma in patients aged ≤18 years were included. Unknown primary and uncertain malignant melanomas were excluded. Three couples of authors independently performed title/abstract screening and two different authors reviewed all the relevant full texts. The selected articles were manually cross‐checked for overlapping data for qualitative synthesis. Subsequently data on single patients were extracted to perform a patient‐level meta‐analysis. PROSPERO registration number: CRD42021233248. The main outcomes were melanoma‐specific survival (MSS) and progression‐free survival (PFS) outcomes. Separate analyses were done of cases with complete information on histologic subtype, focusing on superficial spreading (SSM), nodular (NM) and spitzoid melanomas, as well as of those classified asde‐novo(DNM) and acquired or congenital nevus‐associated melanomas (NAM). The qualitative synthesis covered 266 studies; however, data on single patients were available from 213 studies including 1002 patients. Among histologic subtypes, NM had a lower MSS than both SSM and spitzoid melanoma, and a lower PFS than SSM. Spitzoid melanoma had a significantly higher progression risk than SSM and trended toward lower mortality. Focusing on nevus‐associated status, DNM demonstrated better MSS after progression than congenital NAM, and no differences were highlighted in PFS. Our findings describe the existence of different biological patterns in paediatric melanoma. Specifically, spitzoid melanomas demonstrated intermediate behaviour between SSM and NM and showed a high risk of nodal progression but low mortality. This raises the question of whether spitzoid lesions are being over‐diagnosed as melanoma in childhood.

20 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
GRGaetano Maria Russo
Gaetano Maria Russo
ARAnna Russo
Anna Russo
FUFabrizio Urraro
Fabrizio Urraro
FCFabrizio Cioce
Fabrizio Cioce
LGLuigi Gallo
Luigi Gallo
ARAlfonso Reginelli
Alfonso Reginelli
Basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma are the three main types of nonmelanoma skin cancers and their rates of occurrence and mortality have been steadily rising over the past few decades. For radiologists, it is still difficult to treat patients with advanced nonmelanoma skin cancer. Nonmelanoma skin cancer patients would benefit greatly from an improved diagnostic imaging-based risk stratification and staging method that takes into account patient characteristics. The risk is especially elevated among those who previously received systemic treatment or phototherapy. Systemic treatments, including biologic therapies and methotrexate (MTX), are effective in managing immune-mediated diseases; however, they may increase susceptibility to NMSC due to immunosuppression or other factors. Risk stratification and staging tools are crucial in treatment planning and prognostic evaluation. PET/CT appears more sensitive and superior to CT and MRI for nodal and distant metastasis as well as in surveillance after surgery. The patient treatment response improved with advent and utilization of immunotherapy and different immune-specific criteria are established to standardized evaluation criteria of clinical trials but none of them have been utilized routinely with immunotherapy. The advent of immunotherapy has also arisen new critical issues for radiologists, such as atypical response pattern, pseudo-progression, as well as immune-related adverse events that require early identification to optimize and improve patient prognosis and management. It is important for radiologists to have knowledge of the radiologic features site of the tumor, clinical stage, histological subtype, and any high-risk features to assess immunotherapy treatment response and immune-related adverse events.

29 June 2022 in International Journal of Dermatology
Verified
Journal Article
Closed access
GLGaetano Licata
Gaetano Licata
DBDario Buononato
Dario Buononato
GCGiulia Calabrese
Giulia Calabrese
AGAlessio Gambardella
Alessio Gambardella
GBGiulia Briatico
Giulia Briatico
Giuseppe ArgenzianoGiuseppe Argenziano
Giuseppe Argenziano

1 April 2022 in International Journal of Dermatology
Verified
Journal Article
Open access
GBGiulia Briatico
Giulia Briatico
PMPamela Mancuso
Pamela Mancuso
GAGiuseppe Argenziano
Giuseppe Argenziano
CLCaterina Longo
Caterina Longo
LMLucia Mangone
Lucia Mangone
RPRiccardo Pampena
Riccardo Pampena
Background: In Italy, comprehensive national studies, about mortality rates for cutaneous melanoma, are missing. The aim of this study was to analyze the trend of cutaneous melanoma mortality in Italy from 1982 to 2016.Methods: Data on death certificates were obtained from Italian National Institute of Statistics (ISTAT: Istituto nazionale di STATistica, Indagine sulle cause di morte). Mortality rates were age‐standardized on the European population 2013 and presented per 100,000 individuals. Age‐adjusted mortality rates (AMRs) were calculated by sex, age group, and geographic areas. To identify changes in mortality rate trends, a joinpoint regression model was used, and the annual percent change (APC) was estimated.Results: In Italy, a total number of 49,312 patients (44.0% women) died for cutaneous melanoma from 1982 to 2016. Melanoma mortality rates significantly increased in the study period in both sexes, with higher AMR values and a steeper increase in men (from 2.71 to 4.02; APC: 1.43; 95% CI 1.26–1.61) than women (from 1.94–2.10; APC: 0.23; 95% CI 0.00–0.46). The largest difference between men and women was observed in patients aged ≥65 years with APC of 2.17 in men (95% CI 1.97–2.37) and 0.37 in women (95% CI 0.08–0.66).Conclusion: In conclusion, the melanoma mortality rate in Italy progressively increased especially in elderly men. Several hypotheses might explain the observed age and geographic differences such as sun exposure habits or different strategies of prevention campaigns.

17 March 2021 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
EMElvira Moscarella
Elvira Moscarella
GBGabriella Brancaccio
Gabriella Brancaccio
GBGiulia Briatico
Giulia Briatico
ARAndrea Ronchi
Andrea Ronchi
PVPasquale Verolino
Pasquale Verolino
RARoberto Alfano
Roberto Alfano
Click on the article title to read more.

25 January 2021 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
CGCaterina Maria Rosaria Giorgio
Caterina Maria Rosaria Giorgio
GBGiulia Briatico
Giulia Briatico
GLGaetano Licata
Gaetano Licata
GBGraziella Babino
Graziella Babino
EFElisabetta Fulgione
Elisabetta Fulgione
GAGiuseppe Argenziano
Giuseppe Argenziano